- Home
- LTRN vs GRCE Comparison
LTRN vs GRCE Comparison
Compare LTRN & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- GRCE
- Stock Information
- Founded
- LTRN 2013
- GRCE 2002
- Country
- LTRN United States
- GRCE United States
- Employees
- LTRN N/A
- GRCE N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- GRCE
- Sector
- LTRN Health Care
- GRCE
- Exchange
- LTRN Nasdaq
- GRCE NYSE
- Market Cap
- LTRN 36.0M
- GRCE 42.1M
- IPO Year
- LTRN 2020
- GRCE N/A
- Fundamental
- Price
- LTRN $3.74
- GRCE $3.39
- Analyst Decision
- LTRN Strong Buy
- GRCE Strong Buy
- Analyst Count
- LTRN 1
- GRCE 1
- Target Price
- LTRN $25.00
- GRCE $12.00
- AVG Volume (30 Days)
- LTRN 283.8K
- GRCE 59.2K
- Earning Date
- LTRN 08-07-2025
- GRCE 08-15-2025
- Dividend Yield
- LTRN N/A
- GRCE N/A
- EPS Growth
- LTRN N/A
- GRCE N/A
- EPS
- LTRN N/A
- GRCE N/A
- Revenue
- LTRN N/A
- GRCE N/A
- Revenue This Year
- LTRN N/A
- GRCE N/A
- Revenue Next Year
- LTRN N/A
- GRCE N/A
- P/E Ratio
- LTRN N/A
- GRCE N/A
- Revenue Growth
- LTRN N/A
- GRCE N/A
- 52 Week Low
- LTRN $2.55
- GRCE $1.75
- 52 Week High
- LTRN $6.12
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- LTRN 63.62
- GRCE N/A
- Support Level
- LTRN $3.21
- GRCE N/A
- Resistance Level
- LTRN $3.75
- GRCE N/A
- Average True Range (ATR)
- LTRN 0.24
- GRCE 0.00
- MACD
- LTRN 0.07
- GRCE 0.00
- Stochastic Oscillator
- LTRN 98.65
- GRCE 0.00
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.